Compare ResMed Inc. (RMD) vs Symbotic Inc (SYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Symbotic Inc — how do they compare? ResMed Inc. trades at $194.34 (market cap $28.81B), while Symbotic Inc trades at $42.6 (market cap $5.19B). The key difference: ResMed Inc. is far larger — about 5.6× Symbotic Inc's market cap, and ResMed Inc. pays a 1.21% dividend while Symbotic Inc pays none. Which is the better fit depends on your goals.
| RMD | SYM | |
|---|---|---|
Market Cap | $28.81B | $5.19B |
Sector | Health | Technology |
52-Week High | $293.73 | $87.30 |
52-Week Low | $182.82 | $38.57 |
Enterprise Value | $27.99B | $3.18B |
Dividend Yield | 1.21% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $195.8, down 1.6% on the day, with a bearish technical signal but strong fundamentals. Recent quarterly earnings have consistently beaten estimates, with Q1 2026 EPS of $2.86 exceeding the $2.80 forecast. The company sold its MatrixCare business for $490 million in July 2026 to sharpen focus on connected care, signaling strategic refinement. Revenue growth remains robust, climbing to $5.15 billion in 2025, with net income margins expanding to 27.44%.
The outlook is supported by solid earnings momentum and a consensus price target of $245.88, implying 25.6% upside. Risks include competitive pressures in medical equipment and reliance on sleep apnea market growth. Analyst sentiment is mixed with 40% buy ratings, but institutional selling by Baader Bank in Q1 2026 warrants monitoring.
SYM trades at $40.83, down 1.02% with bearish technical signals despite recent earnings beats. The company shows revenue growth potential with $2.25B in 2025 revenue and improving margins, though net income remains negative. Analyst consensus is bullish with a $57.50 price target, while technical indicators show oversold conditions with RSI at 29.43. Recent news highlights Symbotic's positioning in warehouse robotics and AI automation.
The stock presents a growth opportunity in the expanding warehouse automation market, supported by strong analyst buy ratings and improving financial trends. Key risks include continued negative profitability, high valuation multiples, and competitive pressures in the robotics sector. Near-term catalysts include Q2 2026 earnings and execution on the company's $1.1B projected net cash flow for 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Symbotic Inc
Symbotic is an automation technology leader that provides an end-to-end, A.I.-powered robotic platform for large-scale warehouse operations. By utilizing untethered, high-speed autonomous bots and sophisticated vision systems, Symbotic transforms traditional distribution centers into high-density strategic assets. The company serves the world’s largest retailers and wholesalers—most notably Walmart—while expanding into 'Warehouse-as-a-Service' through its GreenBox joint venture to democratize advanced automation for smaller enterprises.
Read more on SYM →
